Companies: 10,795·Total market cap: $144.5T

Lunai Bioworks Inc.

Lunai Bioworks Inc.

RENBNASDAQHealthcare

$1.42

+$0.00(+0.00%)

Market Cap$32915951

P/E Ratio—

52W High$21

52W Low$1.1208

Avg Volume219K

Open$1.19

Beta0.53

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

Lunai Bioworks Inc.（RENB）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · RENB · 截至 Jun 9, 2026

关键指标

EPS (TTM)$2.11Earnings history

PE Ratio (TTM)0.7×PE Ratio deep dive

Revenue (TTM)192936.00Full revenue history

Dividend Yield不分红Dividend history

Shares Outstanding165.1MShares outstanding history

Next EarningsTBAEarnings history

探索 Lunai Bioworks Inc. 数据

分析师预测—

股息不分红

盈利EPS $-1.08+87.14%

财务快照

FY 2025Revenue$0.00

202320242025

FY 2025Net Income-$178.0M▼ 120.72% YoY

202320242025

FY 2025EPS$-1.08▲ +87.14% YoY

202320242025

TTM:Revenue: $192936.00Net Income: -$128.3MEPS: $2.11View income statement →

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

Lunai Bioworks Inc.

$1.42+0.00%$32.9M #2

$0.33+0.22%$29.7M #3

Angion Biomedica Corp.

$1.00+0.00%$30.1M #4

Freeline Therapeutics Holdings plc

$6.49+0.15%$28.3M #5

Grace Therapeutics, Inc.

$2.30+0.00%$35.6M #6

Opus Genetics, Inc.

$4.03+0.00%$328.0M

股票表现

1D+0.00%

1W+36.54%

1M+11.81%

3M-49.10%

YTD-81.39%

1Y-73.70%

5Y-95.34%

关于 Lunai Bioworks Inc.

CEODavid H. Weinstein

IPO DateFeb 7, 2018

Employees25

CountryUS

Websiterenovarogroup.com

Lunai Bioworks Inc. Lunai Bioworks, Inc. functions as a pre-clinical stage biotechnology enterprise, concentrating its efforts on pioneering genetically modified cell and immunotherapeutic platforms. These advanced techn…

Biotechnology HealthcareNASDAQUS

关于股票概览与关键数据

Lunai Bioworks Inc.（RENB）是 Biotechnology 行业的 Healthcare 类公司，于 Feb 7, 2018 在 NASDAQ 上市。截至最近交易日，RENB 股价为 $1.42，市值约为 $32.9M。过去12个月累计回报 -73.70%，年初至今回报 -81.39%。

2025 财年 Lunai Bioworks Inc. 营收 —。完整财务数据（营收历史、盈利、资产负债表）请使用上方标签页。

常见问题

截至最近一个交易日，Lunai Bioworks Inc.（RENB）股价为 $1.42，在 NASDAQ 上市，52周区间为 $1.12 – $21.00。

RENB 最新股价RENB quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 9, 2026本内容不构成投资建议